These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7916928)

  • 1. Long-term outcome of the use of OKT3 to treat steroid-resistant acute renal allograft rejection.
    Rowe PA; Fan KS; Gardiner DS; Macpherson SG; Bradley JA; Rodger RS; Junor BJ; Briggs JD
    Transpl Int; 1994 Jul; 7(4):278-83. PubMed ID: 7916928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants.
    Mochon M; Kaiser B; Palmer JA; Polinsky M; Flynn JT; Caputo GC; Baluarte HJ
    Pediatr Nephrol; 1993 Jun; 7(3):259-62. PubMed ID: 8518094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection.
    Midtvedt K; Tafjord AB; Hartmann A; Eide TC; Holdaas H; Nordal KP; Draganov B; Sødal G; Leivestad T; Fauchald P
    Transplantation; 1996 Jul; 62(1):38-42. PubMed ID: 8693541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OKT3 therapy in addition to tacrolimus is associated with improved long-term function in patients with steroid refractory renal allograft rejection.
    Patschan D; Kribben A; Pietruck F; Lutz J; Binek M; Philipp T; Heemann U; Witzke O
    Nephron Clin Pract; 2006; 103(3):c94-9. PubMed ID: 16534238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OKT3 for the treatment of steroid-resistant acute renal allograft rejection.
    Jogose JT; Bailey RR; Lynn KL; Robson RA; Wells JE
    Nephron; 1997; 77(3):298-303. PubMed ID: 9375823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation.
    Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D
    Am J Nephrol; 1999; 19(6):634-40. PubMed ID: 10592356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
    Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
    Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection.
    Kamath S; Dean D; Peddi VR; Schroeder TJ; Alexander JW; Cavallo T; First MR
    Transplantation; 1997 Nov; 64(10):1428-32. PubMed ID: 9392306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
    Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR
    Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OKT3 rescue for steroid-resistant rejection in adult liver transplantation.
    Solomon H; Gonwa TA; Mor E; Holman MJ; Gibbs J; Watemberg I; Netto G; Goldstein RM; Husberg BS; Klintmalm GB
    Transplantation; 1993 Jan; 55(1):87-91. PubMed ID: 8420070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
    Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
    Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
    [No Abstract]   [Full Text] [Related]  

  • 12. [OKT3 treatment of refractory renal allograft rejection].
    Xu J; Ma J; Bai X
    Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract]   [Full Text] [Related]  

  • 14. [Orthoclone OKT3 in the treatment of intractable acute renal allograft rejection].
    Yu LX
    Zhonghua Wai Ke Za Zhi; 1993 Dec; 31(12):754-5. PubMed ID: 8033708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effects of the treatment for acute rejection with OKT3 monoclonal antibody treatment on the long-term results of cadaveric kidney transplantation].
    Kinukawa T; Hattori R; Ohshima S; Matsuura O; Takeuchi N; Fujita T; Nishiyama N; Ono Y; Sahashi M; Yamada S
    Nihon Hinyokika Gakkai Zasshi; 1993 Oct; 84(10):1851-6. PubMed ID: 8255049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OKT3 for primary therapy of the first rejection episode in kidney transplants.
    Tesi RJ; Elkhammas EA; Henry ML; Ferguson RM
    Transplantation; 1993 May; 55(5):1023-9. PubMed ID: 8497875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
    Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ
    Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of OKT3 treatment for steroid resistant rejection of renal allografts: the long-term outcome at a single center.
    Inui M; Tanabe K; Ishikawa N; Tokumoto T; Harano M; Otsubo S; Suzuki K; Goya N; Yagisawa T; Nakazawa H; Fuchinoue S; Toma H
    Transplant Proc; 1999 Nov; 31(7):2870-1. PubMed ID: 10578320
    [No Abstract]   [Full Text] [Related]  

  • 19. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and renal histologic predictors of long-term outcome after OKT3 therapy for steroid-resistant rejection.
    Wiener Y; Nakhleh RE; Kupin WL; Lee M; Escobar FS; Venkat KK; Mozes MF
    Transplant Proc; 1995 Feb; 27(1):1014-5. PubMed ID: 7878781
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.